CN102253141B - 高效液相串联质谱分析系统及其分析法 - Google Patents
高效液相串联质谱分析系统及其分析法 Download PDFInfo
- Publication number
- CN102253141B CN102253141B CN2011101725758A CN201110172575A CN102253141B CN 102253141 B CN102253141 B CN 102253141B CN 2011101725758 A CN2011101725758 A CN 2011101725758A CN 201110172575 A CN201110172575 A CN 201110172575A CN 102253141 B CN102253141 B CN 102253141B
- Authority
- CN
- China
- Prior art keywords
- high performance
- performance liquid
- sample
- experiment
- analysis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 31
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 title abstract description 11
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 title abstract description 5
- 239000000523 sample Substances 0.000 claims abstract description 39
- 239000007788 liquid Substances 0.000 claims abstract description 35
- 238000004458 analytical method Methods 0.000 claims abstract description 30
- 239000012472 biological sample Substances 0.000 claims abstract description 27
- 238000002474 experimental method Methods 0.000 claims abstract description 27
- 238000006243 chemical reaction Methods 0.000 claims abstract description 17
- 238000012545 processing Methods 0.000 claims abstract description 13
- 238000010790 dilution Methods 0.000 claims abstract description 12
- 239000012895 dilution Substances 0.000 claims abstract description 12
- 239000006228 supernatant Substances 0.000 claims abstract description 10
- 238000007877 drug screening Methods 0.000 claims abstract description 9
- 230000008569 process Effects 0.000 claims abstract description 7
- 239000002904 solvent Substances 0.000 claims abstract description 4
- 238000002347 injection Methods 0.000 claims abstract description 3
- 239000007924 injection Substances 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 31
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 30
- 238000001819 mass spectrum Methods 0.000 claims description 27
- 150000001875 compounds Chemical class 0.000 claims description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- 230000002503 metabolic effect Effects 0.000 claims description 12
- 238000013459 approach Methods 0.000 claims description 9
- 230000012447 hatching Effects 0.000 claims description 9
- 238000005070 sampling Methods 0.000 claims description 9
- 238000012360 testing method Methods 0.000 claims description 9
- 239000012071 phase Substances 0.000 claims description 8
- 239000007791 liquid phase Substances 0.000 claims description 7
- 238000012216 screening Methods 0.000 claims description 7
- 102000004506 Blood Proteins Human genes 0.000 claims description 5
- 108010017384 Blood Proteins Proteins 0.000 claims description 5
- 210000005229 liver cell Anatomy 0.000 claims description 5
- 230000035699 permeability Effects 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 3
- 230000003993 interaction Effects 0.000 claims description 3
- 238000004949 mass spectrometry Methods 0.000 claims description 3
- 238000007405 data analysis Methods 0.000 claims description 2
- 230000016507 interphase Effects 0.000 claims description 2
- 238000011534 incubation Methods 0.000 abstract description 6
- 239000002547 new drug Substances 0.000 abstract description 4
- 238000000338 in vitro Methods 0.000 abstract description 3
- 239000003814 drug Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 238000005457 optimization Methods 0.000 description 6
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 6
- 238000001514 detection method Methods 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 239000012981 Hank's balanced salt solution Substances 0.000 description 4
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 4
- 229960005156 digoxin Drugs 0.000 description 4
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000004907 flux Effects 0.000 description 4
- HQVFCQRVQFYGRJ-UHFFFAOYSA-N formic acid;hydrate Chemical compound O.OC=O HQVFCQRVQFYGRJ-UHFFFAOYSA-N 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000012452 mother liquor Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229960003604 testosterone Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 3
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 3
- 102100030306 TBC1 domain family member 9 Human genes 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 238000003287 bathing Methods 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 3
- 229960001259 diclofenac Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000013537 high throughput screening Methods 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 2
- LIFAQMGORKPVDH-UHFFFAOYSA-N 7-ethoxycoumarin Chemical compound C1=CC(=O)OC2=CC(OCC)=CC=C21 LIFAQMGORKPVDH-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 2
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 2
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 229960002274 atenolol Drugs 0.000 description 2
- 238000000889 atomisation Methods 0.000 description 2
- 230000009087 cell motility Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 229960001022 fenoterol Drugs 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 238000002514 liquid chromatography mass spectrum Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 210000001589 microsome Anatomy 0.000 description 2
- 238000002552 multiple reaction monitoring Methods 0.000 description 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 2
- JWHAUXFOSRPERK-UHFFFAOYSA-N propafenone Chemical compound CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 JWHAUXFOSRPERK-UHFFFAOYSA-N 0.000 description 2
- 229960000203 propafenone Drugs 0.000 description 2
- 229960003712 propranolol Drugs 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000197 pyrolysis Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960001722 verapamil Drugs 0.000 description 2
- GMHKMTDVRCWUDX-LBPRGKRZSA-N (S)-Mephenytoin Chemical compound C=1C=CC=CC=1[C@]1(CC)NC(=O)N(C)C1=O GMHKMTDVRCWUDX-LBPRGKRZSA-N 0.000 description 1
- MJKVTPMWOKAVMS-UHFFFAOYSA-N 3-hydroxy-1-benzopyran-2-one Chemical class C1=CC=C2OC(=O)C(O)=CC2=C1 MJKVTPMWOKAVMS-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 101710088105 Isocitrate dehydrogenase [NAD] subunit 1, mitochondrial Proteins 0.000 description 1
- 101710086399 Isocitrate dehydrogenase [NAD] subunit 2, mitochondrial Proteins 0.000 description 1
- 102100021332 Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial Human genes 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- XBJFCYDKBDVADW-UHFFFAOYSA-N acetonitrile;formic acid Chemical compound CC#N.OC=O XBJFCYDKBDVADW-UHFFFAOYSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000012362 drug development process Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- ODBLHEXUDAPZAU-UHFFFAOYSA-N isocitric acid Chemical class OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960003893 phenacetin Drugs 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011101725758A CN102253141B (zh) | 2011-06-24 | 2011-06-24 | 高效液相串联质谱分析系统及其分析法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011101725758A CN102253141B (zh) | 2011-06-24 | 2011-06-24 | 高效液相串联质谱分析系统及其分析法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102253141A CN102253141A (zh) | 2011-11-23 |
CN102253141B true CN102253141B (zh) | 2012-11-21 |
Family
ID=44980522
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011101725758A Active CN102253141B (zh) | 2011-06-24 | 2011-06-24 | 高效液相串联质谱分析系统及其分析法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102253141B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103364510B (zh) * | 2012-03-27 | 2015-01-07 | 中国科学院大连化学物理研究所 | Hplc-ms/ms结合代谢流量分析系统评估环境污染物细胞毒性的方法 |
CN103293253B (zh) * | 2013-05-24 | 2015-04-01 | 中国科学院过程工程研究所 | 生物技术药物高效纯化分析系统及其药物分离检测方法 |
CN105335165A (zh) * | 2015-12-04 | 2016-02-17 | 济南大学 | 一种循环伏安数据的自动分离方法 |
CN106053689B (zh) * | 2016-07-18 | 2017-10-20 | 华南理工大学 | 可精确获取采样时间的手动停流型二维液相色谱及其应用 |
CN106841421A (zh) * | 2016-12-30 | 2017-06-13 | 广州中大南沙科技创新产业园有限公司 | 一种药代动力学早期成药性评估方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1251615A (zh) * | 1997-02-14 | 2000-04-26 | 乔治华盛顿大学 | 测量dna合成率的分析方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030004653A1 (en) * | 1996-05-24 | 2003-01-02 | Michael Flavin | Automated technology of screening of stationary phases |
JP3764421B2 (ja) * | 2000-10-03 | 2006-04-05 | ダイオネックス コーポレイション | 液体クロマトグラフィ−質量分析計(lc−ms)分析におけるピークパーキングのための方法及びシステム |
JP2004108958A (ja) * | 2002-09-19 | 2004-04-08 | Jeol Ltd | ガスクロマトグラフ質量分析装置 |
-
2011
- 2011-06-24 CN CN2011101725758A patent/CN102253141B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1251615A (zh) * | 1997-02-14 | 2000-04-26 | 乔治华盛顿大学 | 测量dna合成率的分析方法 |
Non-Patent Citations (3)
Title |
---|
JP特开2004-108958A 2004.04.08 |
贾韦韬等.高效液相色谱检测器——高分辨飞行时间质谱仪的研制.《质谱学报》.2006,第27卷(第3期), * |
陈小华.吉尔森自动化固相萃取仪及其在样品前处理中的应用.《分析测试仪器通讯》.1996,第6卷(第4期), * |
Also Published As
Publication number | Publication date |
---|---|
CN102253141A (zh) | 2011-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102253141B (zh) | 高效液相串联质谱分析系统及其分析法 | |
Humphrey et al. | High-throughput and high-sensitivity phosphoproteomics with the EasyPhos platform | |
Peisl et al. | Dark matter in host-microbiome metabolomics: tackling the unknowns–a review | |
Alexovič et al. | Recent advances in robotic protein sample preparation for clinical analysis and other biomedical applications | |
Kim et al. | NMR-based plant metabolomics: where do we stand, where do we go? | |
León et al. | Mammalian cell metabolomics: experimental design and sample preparation | |
Gronquist et al. | Exploring uncharted terrain in nature's structure space using capillary NMR spectroscopy: 13 steroids from 50 fireflies | |
US20130316462A1 (en) | Rapid and high-throughput analysis of sterols/stanols or derivatives thereof | |
Luippold et al. | An integrated platform for fully automated high-throughput LC–MS/MS analysis of in vitro metabolic stability assay samples | |
CN101315354A (zh) | 一种水环境中痕量双酚a浓度的检测方法 | |
Zhang et al. | Recent advance in the discovery of tyrosinase inhibitors from natural sources via separation methods | |
Kampe et al. | Modular microfluidic system for emulation of human phase I/phase II metabolism | |
Johnston et al. | Rapid, One-Step Sample Processing for Label-Free Single-Cell Proteomics | |
CN112485442A (zh) | 一种基于化学蛋白质组学的小分子靶标筛选方法及其应用 | |
CN101021467A (zh) | 一种单胺氧化酶活性的荧光检测方法 | |
Pirog et al. | Comparison of different digestion methods for proteomic analysis of isolated cells and FFPE tissue samples | |
Derfus et al. | Cell culture monitoring via an auto‐sampler and an integrated multi‐functional off‐line analyzer | |
CN101581727A (zh) | 一种高效检测体内蛋白相互作用的方法 | |
Xie et al. | Simultaneous affinity enrichment of two post-translational modifications for quantification and site localization | |
CN102539592A (zh) | 检测体液中极长链脂肪酸含量的方法 | |
CN110873766B (zh) | 筛选药物引起结构和相互作用变化蛋白质的质谱分析方法 | |
CN103430890A (zh) | 一种斑马鱼体内ros检测模型的建立方法及其应用 | |
Wang et al. | Pick-up single-cell proteomic analysis for quantifying up to 3000 proteins in a tumor cell | |
CN103926368B (zh) | 从玉米浆中提取生物素的方法及其薄层层析扫描检测方法 | |
Wu et al. | Micro sequential injection system as the interfacing device for process analytical applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: WUXI APPTEC CO.,LTD. Free format text: FORMER OWNER: SHANGHAI YAOMING KANGDE NEW MEDICINE DEVELOPMENT CO., LTD. Effective date: 20121106 Owner name: SHANGHAI YAOMING KANGDE NEW MEDICINE DEVELOPMENT C Effective date: 20121106 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 200131 PUDONG NEW AREA, SHANGHAI TO: 214092 WUXI, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20121106 Address after: 214092, Wuxi, Jiangsu province Binhu District Ma Shan Mei Liang West Road, No. 88 Patentee after: Wuxi AppTec Biological Technology Co., Ltd. Patentee after: Shanghai Yaoming Kangde New Medicine Development Co., Ltd. Patentee after: Suzhou AppTec Co., Ltd. Address before: 200131 Shanghai City, Pudong New Area Waigaoqiao Free Trade Zone Foote Road No. 288 Patentee before: Shanghai Yaoming Kangde New Medicine Development Co., Ltd. |
|
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 214092, Wuxi, Jiangsu province Binhu District Ma Shan Mei Liang West Road, No. 88 Patentee after: Wuxi AppTec Biological Technology Co., Ltd. Patentee after: Shanghai Yaoming Kangde New Medicine Development Co., Ltd. Patentee after: Suzhou medicine bright Kant's new drug development limited company Address before: 214092, Wuxi, Jiangsu province Binhu District Ma Shan Mei Liang West Road, No. 88 Patentee before: Wuxi AppTec Biological Technology Co., Ltd. Patentee before: Shanghai Yaoming Kangde New Medicine Development Co., Ltd. Patentee before: Suzhou AppTec Co., Ltd. |
|
C56 | Change in the name or address of the patentee |
Owner name: WUXI YAOMING KANGDE BIO-TECHNOLOGY CO., LTD. Free format text: FORMER NAME: WUXI APPTEC CO.,LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 214092, Wuxi, Jiangsu province Binhu District Ma Shan Mei Liang West Road, No. 88 Patentee after: WUXI APPTEC BIOPHARMACEUTICALS CO., LTD. Patentee after: Shanghai Yaoming Kangde New Medicine Development Co., Ltd. Patentee after: Suzhou medicine bright Kant's new drug development limited company Address before: 214092, Wuxi, Jiangsu province Binhu District Ma Shan Mei Liang West Road, No. 88 Patentee before: Wuxi AppTec Biological Technology Co., Ltd. Patentee before: Shanghai Yaoming Kangde New Medicine Development Co., Ltd. Patentee before: Suzhou medicine bright Kant's new drug development limited company |
|
TR01 | Transfer of patent right |
Effective date of registration: 20171207 Address after: 214092, Wuxi, Jiangsu province Binhu District Ma Shan Mei Liang West Road, No. 88 Patentee after: WUXI APPTEC BIOPHARMACEUTICALS CO., LTD. Address before: 214092, Wuxi, Jiangsu province Binhu District Ma Shan Mei Liang West Road, No. 88 Co-patentee before: Shanghai Yaoming Kangde New Medicine Development Co., Ltd. Patentee before: WUXI APPTEC BIOPHARMACEUTICALS CO., LTD. Co-patentee before: Suzhou medicine bright Kant's new drug development limited company |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180411 Address after: 214092, Wuxi, Jiangsu province Binhu District Ma Shan Mei Liang West Road, No. 88 Co-patentee after: SUZHOU YAOMING KANGDE INSPECTION TESTING CO., LTD. Patentee after: WUXI APPTEC BIOPHARMACEUTICALS CO., LTD. Address before: 214092, Wuxi, Jiangsu province Binhu District Ma Shan Mei Liang West Road, No. 88 Patentee before: WUXI APPTEC BIOPHARMACEUTICALS CO., LTD. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 214092 No. 88, Mashan Meiliang West Road, Binhu District, Wuxi City, Jiangsu Province Co-patentee after: SUZHOU YAOMING KANGDE INSPECTION TESTING CO., LTD. Patentee after: Wuxi Yaoming Biotechnology Co., Ltd. Address before: 214092 No. 88, Mashan Meiliang West Road, Binhu District, Wuxi City, Jiangsu Province Co-patentee before: SUZHOU YAOMING KANGDE INSPECTION TESTING CO., LTD. Patentee before: WUXI APPTEC BIOPHARMACEUTICALS CO., LTD. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 214092 No. 88, Mashan Meiliang West Road, Binhu District, Wuxi City, Jiangsu Province Co-patentee after: Suzhou Pharmacopoeia Testing and Inspection Co., Ltd. Patentee after: Wuxi Yaoming Biotechnology Co., Ltd. Address before: 214092 No. 88, Mashan Meiliang West Road, Binhu District, Wuxi City, Jiangsu Province Co-patentee before: SUZHOU YAOMING KANGDE INSPECTION TESTING CO., LTD. Patentee before: Wuxi Yaoming Biotechnology Co., Ltd. |